Assessment of Efficacy and Safety of Desensitization Therapy with Intravenous Immunoglobulin in Preformed Donor-Specific Antibody-Positive Kidney Transplant Patients (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO1209; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Currently, widely used methods for DSA desensitization therapy include plasma exchange and combination therapy with low- or high-dose intravenous immunoglobulin (IVIG) and rituximab (RTX anti-CD20 antibody)...Conclusion Desensitization therapy with IVIG and RTX contributes to the prevention of ABMR in the short term in DSA-positive kidney transplant and graft survival. Further studies are needed to evaluate the efficacy of the current protocol and the long-term prognosis related to chronic kidney disease."
Clinical • Antibody-mediated Rejection • Chronic Kidney Disease • Cytomegalovirus Infection • Infectious Disease • Nephrology • Transplantation
|
|
Tomoya Naka; Jun Matsushita; Hiroko Ueda; Kazunori Someya; Xuyen Thi Pham; Masaaki Yanishi; Hi Kinoshita; Hiroyasu Tsukaguchi
|